Effect of Nonalcoholic Fatty Liver Disease on the Development of Type 2 Diabetes in Nonobese, Nondiabetic Korean Men

被引:27
作者
Chon, Chang Wook [1 ]
Kim, Bum Soo [2 ]
Cho, Yong Kyun [1 ]
Sung, Ki Chul [2 ]
Bae, Ji Cheol [3 ]
Kim, Tae Wan [1 ]
Won, Hyun Sun [1 ]
Joo, Kwan Joong [4 ]
机构
[1] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Gastroenterol & Hepatol,Dept Internal Med, Seoul 110746, South Korea
[2] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Div Cardiol,Dept Internal Med, Seoul 110746, South Korea
[3] Sungkyunkwan Univ, Kangbuk Samsung Hosp, Div Endocrinol & Metab, Dept Internal Med,Samsung Med Ctr,Sch Med, Seoul 110746, South Korea
[4] Sungkyunkwan Univ, Sch Med, Kangbuk Samsung Hosp, Dept Urol, Seoul 110746, South Korea
关键词
Nonalcoholic fatty liver disease; Type 2 diabetes mellitus; Metabolic syndrome; INSULIN-RESISTANCE; RISK-FACTORS; METABOLIC SYNDROME; STEATOHEPATITIS; PREVALENCE; ACCUMULATION; ASSOCIATION; SHANGHAI; GLUCOSE; OBESITY;
D O I
10.5009/gnl.2012.6.3.368
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We have a limited understanding of the effect of nonalcoholic fatty liver disease (NAFLD) on the development of type 2 diabetes. Methods: The study subjects included male who had received biennial medical checkups between 2005 and 2009 and who had been diagnosed with fatty liver disease. The subjects with sustained NAFLD (FL, n=107) and sustained non-NAFLD (NFL, n=1,054) were followed to determine the development of type 2 diabetes. Results: In the FL group, there were more subjects with impaired fasting glucose (IFG), type 2 diabetes and high HOMA-IR than there were in the NFL group during the 5-year follow-up period (32.7 vs. 17.6%, 1.9 vs. 0.3%, 17.9 vs. 5.2% respectively, p<0.05). The FL group showed a higher risk than NFL group for abnormal glucose metabolism as determined using IFG (odds ratio [OR], 2.13; confidence interval [Cl], 1.36 to 3.35), type 2 diabetes (OR, 7.63; 95% Cl, 1.03 to 56.79) and high HOMA-IR (OR, 3.25; 95% Cl, 1.79 to 5.91) and metabolic parameters such as body mass index (OR, 3.35; 95% Cl, 1.87 to 6.02), triglyceride (OR, 3.05; 95% Cl, 1.92 to 4.86) and fasting blood sugar (OR, 2.18; 95% Cl, 1.39 to 3.41). Conclusions: Sustained NAFLD appears to be associated with an increased risk for the development of type 2 diabetes and deterioration of metabolic parameters in nonobese, non-diabetic Korean men. (Gut Liver 2012;6:368-373)
引用
收藏
页码:368 / 373
页数:6
相关论文
共 31 条
[1]  
Amer Diabet Assoc, 2011, DIABETES CARE, V34, pS11, DOI [10.2337/dc10-S062, 10.2337/dc14-S081, 10.2337/dc11-S011, 10.2337/dc13-S011, 10.2337/dc13-S067, 10.2337/dc12-s064, 10.2337/dc11-S062, 10.2337/dc10-S011, 10.2337/dc12-s011]
[2]   Impact of Nonalcoholic Fatty Liver Disease on Insulin Resistance in Relation to HbA1c Levels in Nondiabetic Subjects [J].
Bae, Ji Cheol ;
Cho, Yong Kyun ;
Lee, Won Young ;
Seo, Hyun Il ;
Rhee, Eun Jung ;
Park, Se Eun ;
Park, Cheol Young ;
Oh, Ki Won ;
Sung, Ki Chul ;
Kim, Byung Ik .
AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 (11) :2389-2395
[3]   Prevalence of and risk factors for nonalcoholic fatty liver disease: The Dionysos Nutrition and Liver Study [J].
Bedogni, G ;
Miglioli, L ;
Masutti, F ;
Tiribelli, C ;
Marchesini, G ;
Bellentani, S .
HEPATOLOGY, 2005, 42 (01) :44-52
[4]   Nonalcoholic steatohepatitis: Definition and pathology [J].
Brunt, EM .
SEMINARS IN LIVER DISEASE, 2001, 21 (01) :3-16
[5]   Clinical aspects of fatty liver disease [J].
Choudhury, J ;
Sanyal, AJ .
SEMINARS IN LIVER DISEASE, 2004, 24 (04) :349-362
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
Day C P, 2002, J Gastroenterol Hepatol, V17 Suppl 3, pS377, DOI 10.1046/j.1440-1746.17.s3.31.x
[8]   The metabolic syndrome [J].
Eckel, RH ;
Grundy, SM ;
Zimmet, PZ .
LANCET, 2005, 365 (9468) :1415-1428
[9]   Survival and causes of death in patients with elevated liver enzymes associated with non-alcoholic fatty liver disease (NAFLD) [J].
Ekstedt, M. ;
Franzen, L. E. ;
Mathiesen, U. L. ;
Holmqvist, M. ;
Bodemar, G. ;
Kechagias, S. .
JOURNAL OF HEPATOLOGY, 2006, 44 :S40-S41
[10]   Fatty liver and the metabolic syndrome among Shanghai adults [J].
Fan, JG ;
Zhu, JN ;
Li, XJ ;
Chen, L ;
Lu, YS ;
Li, L ;
Dai, F ;
Li, F ;
Chen, SY .
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2005, 20 (12) :1825-1832